Does extended pre quit bupropion aid in extinguishing smoking behavior?

Nicotine and Tobacco Research

Volumn 17, Issue 11, 2015, Pages 1377-1384

  Hawk, Larry W ^a,b   Ashare, Rebecca L ^a,c   Rhodes, Jessica D ^a,d   Oliver, Jason A ^a,e   Cummings, Kenneth Michael ^b,f   Mahoney, Martin C ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COTININE; PLACEBO; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; ADOLESCENT; AGED; BLOOD; COUNSELING; DRUG ADMINISTRATION; DRUG THERAPY; PROCEDURES; SMOKING; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; COTININE; COUNSELING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; SMOKING; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946737449     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntu347     Document Type: Article

References (75)

1. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
2. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
3. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Service. Public Health Service; 2008.
4. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.
5. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
6. Baker TB, Mermelstein R, Collins LM, et al. New methods for tobacco dependence treatment research. Ann Behav Med. 2011;41:192-207.
7. Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov. 2007;6:746-762.
8. Group NCITRI. Tobacco Research Implementation Plan. Bethesda, MD: National Cancer Institute, National Institutes of Health; 1998.
9. Lerman C, Roth D, Kaufmann V, et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002;67:219-223.
10. Piper ME, Federmen EB, McCarthy DE, et al. Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol. 2008;117:94-105.
11. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321-327.
12. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12:178-207.
13. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol. 2005;10:219-231.
14. Rauhut AS, Dwoskin LP, Bardo MT. Tolerance does not develop to the decrease in nicotine self-administration produced by repeated bupropion administration. Nicotine Tob Res. 2005;7:901-907.
15. Shoaib M, Sidhpura N, Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl). 2003;165:405-412.
16. Liu X, Caggiula AR, Palmatier MI, Donny EC, Sved AF. Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose. Psychopharmacology (Berl). 2008;196:365-375.
17. Wilkinson JL, Carroll FI, Bevins RA. An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine. J Psychopharmacol. 2010;24:817-828.
18. Paterson NE, Balfour DJ, Markou A. Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob Res. 2008;10:995-1008.
19. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl). 2003;168:347-358.
20. Perkins KA, Karelitz JL, Jao NC, Stratton E. Possible reinforcement enhancing effects of bupropion during initial smoking abstinence. Nicotine Tob Res. 2013;15:1141-1145.
21. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008;197:371-377.
22. Hatsukami DK, Rennard S, Patel MK, et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am J Med. 2004;116:151-157.
23. Cousins MS, Stamat HM, de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl). 2001;157:243-253.
24. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharm. 1998;6:331-343.
25. Steinberg ML, Williams JM. Extinction burst after varenicline titration: a case report. J Smok Cessat. 2013;8:115-118.
26. Bouton ME, Nelson JB. The role of context in classical conditioning: Some implications for cognitive behavior therapy. In: O'Donohue WT, ed. Learning and Behavior Therapy. Needham Heights, MA: Allyn & Bacon; 1998:59-84.
27. Collins BN, Nair US, Komaroff E. Smoking cue reactivity across massed extinction trials: negative affect and gender effects. Addict Behav. 2011;36:308-314.
28. Bouton ME, Winterbauer NE, Todd TP. Relapse processes after the extinction of instrumental learning: renewal, resurgence, and reacquisition. Behav Processes. 2012;90:130-141.
29. Bouton ME. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol. 2000;19(suppl 1):57-63.
30. Conklin CA, Tiffany ST. Applying extinction research and theory to cueexposure addiction treatments. Addiction. 2002;97:155-167.
31. Collins BN, Brandon TH. Effects of extinction context and retrieval cues on alcohol cue reactivity among nonalcoholic drinkers. J Consult Clin Psychol. 2002;70:390-397.
32. Perkins K, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl). 2006;184:628-636.
33. Perkins KA, Lerman C. An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology (Berl). 2014;231:1-11.
34. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med. 2011;171:770-777.
35. Hawk LW Jr, Ashare RL, Lohnes SF, et al. The effects of extended pre quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. Clin Pharmacol Ther. 2012;91:172-180.
36. Rose JE, Herskovic JE, Behm FM, Westman EC. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Nicotine Tob Res. 2009;11:1067-1075.
37. Rose JE. Nicotine preloading: the importance of a pre-cessation reduction in smoking behavior. Psychopharmacology. 2011;217:453-454.
38. Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiat. 1997;12:224-231.
39. Lerman C, Shields PG, Wileyto EP, et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003;22:541-548.
40. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.
41. Shiffman S, Shadel WG, Niaura R, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl). 2003;166:343-350.
42. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289-294.
43. Westman EC, Behm FM, Rose JE. Dissociating the nicotine and airway sensory effects of smoking. Pharmacol Biochem Behav. 1996;53:309-315.
44. Shiffman S. Ecological momentary assessment (EMA) in studies of substance use. Psychol Assess. 2009;21:486-497.
45. Rose JE, Behm FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res. 2006;8:89-101.
46. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5:13-25.
47. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000;117:758-763.
48. Bailey SR, Bryson SW, Killen JD. Predicting successful 24-hr quit attempt in a smoking cessation intervention. Nicotine Tob Res. 2011;13:1092-1097.
49. SRNT. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159.
50. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA. 1994;271:589-594.
51. Ferguson SG, Gitchell JG, Shiffman S, Sembower MA. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, doubleblind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers. Clin Ther. 2009;31:1957-1965.
52. Ashare RL, Wileyto EP, Perkins KA, Schnoll RA. The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. J Addict Med. 2013;7:249-254.
53. Glover ED, Laflin MT, Schuh KJ, et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction. 2007;102:795-802.
54. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer-Verlag; 2000.
55. Benowitz NL, Hatsukami D. Gender differences in the pharmacology of nicotine addiction. Addiction Biology. 1998;3:383-404.
56. Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res. 1999;1:301-315.
57. Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of Nicotine Replacement Therapy for Smoking Cessation: differences between men and women. J Consult Clin Psychol. 2004;72:712-722.
58. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10:1245-1250.
59. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1-32.
60. Rose J. New findings on nicotine addiction and treatment. In: Caggiula AR, Bevins RA, eds. The Motivational Impact of Nicotine and its Role in Tobacco Use. Vol 55. New York City: Springer US; 2009:131-141.
61. Becker KM, Rose JE, Albino AP. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine Tob Res. 2008;10:1139-1148.
62. Zhu AZ, Renner CC, Hatsukami DK, et al. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race and sex. Cancer Epidemiol Biomarkers Prev. 2013;22:708-718.
63. Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA. Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. J Psychopharmacol. 2012;26:1383-1390.
64. Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction. 2008;103:557-563.
65. Bouton ME, Westbrook RF, Corcoran KA, Maren S. Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol Psychiatry. 2006;60:352-360.
66. Bouton ME. Context and behavioral processes in extinction. Learn Mem. 2004;11:485-494.
67. Bouton ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52:976-986.
68. Conklin CA. Environments as cues to smoke: implications for human extinction-based research and treatment. Exp Clin Psychopharmacol. 2006;14:12-19.
69. Hughes JR, Russ CI, Arteaga CE, Rennard SI. Efficacy of a flexible quit date versus an a priori quit date approach to smoking cessation: a crossstudy analysis. Addict Behav. 2011;36:1288-1291.
70. Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. A J Psychiatry. 2013;170:860-867.
71. Winterbauer NE, Lucke S, Bouton ME. Some factors modulating the strength of resurgence after extinction of an instrumental behavior. Learn Motiv. 2013;44:60-71.
72. Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl). 2006;184:353-366.
73. Lloyd DR, Hausknecht KA, Richards JB. Nicotine and methamphetamine disrupt habituation of sensory reinforcer effectiveness in male rats. Exp Clin Psychopharmacol. 2014;22:166-175.
74. Donny EC, Chaudhri N, Caggiula AR, et al. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl). 2003;169:68-76.
75. Palmatier MI, Levin ME, Mays KL, Donny EC, Caggiula AR, Sved AF. Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology (Berl). 2009;207:381-390.